Articles tagged with Immunology
Allergen immunotherapy (AIT) is showing promising results in reducing clinical symptoms and severity of allergic diseases, including asthma and allergic rhinitis. The latest advances in AIT include innovative technologies and biomarkers that predict and monitor treatment response.
Researchers found that microplastics clog liver phagocytes, disrupting metabolism and leading to fatty liver disease. In contrast, smaller particles activated brown adipose tissue, stimulating heat production.
A University of Maryland study predicts that repealing Florida's measles vaccine mandate could spark the largest measles epidemic in the US in nearly 500 years. The study shows that even without mandate removal, Florida's vaccine-induced herd immunity threshold is below the level needed to protect against sustained transmission.
Group 2 innate lymphoid cells (ILC2s) form tight anatomical associations with sensory, autonomic, and enteric nerve fibers, receiving neural regulation through activating and inhibitory pathways. ILC2s also secrete cytokines that can act back on neurons, forming positive feedback loops that modulate allergic and anti-infective immunity.
A novel autologous gene therapy for Wiskott-Aldrich syndrome has demonstrated durable clinical benefits in a phase 3 study, with 96% survival at 1 and 5 years. The treatment, etu-cel, has also reduced severe infections and moderate-to-severe bleeding events.
Researchers found that a natural enzyme derived from figleaf gourd can significantly reduce the immunoreactivity of peanut proteins, pointing to a potential new approach to developing food ingredients with reduced allergenic potential. Enzymatic hydrolysis can alter protein properties, reducing antibody recognition, but not eliminating...
Researchers discovered a link between the nervous system and the development of neuroendocrine prostate cancer, a form of prostate cancer that is aggressive and resistant to treatment. The study found that high levels of a neurotransmitter called neuromedin U support tumor progression by blocking the immune response.
Researchers found that AS01 adjuvant induces trained immunity in human monocytes and reduces tumor growth in selected mouse cancer models. The treatment also alters the tumor microenvironment, increasing frequencies of immune cells and reducing tumor-associated macrophages.
Researchers found similar diarrhea outcomes among patients with low and normal fecal elastase levels, suggesting stool dilution is a possible cause. Fecal fat testing is recommended before enzyme therapy to confirm exocrine pancreatic insufficiency.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Researchers found that sensory neurons retain a memory of allergens that may explain why allergies develop over time. This memory primes neurons to respond more strongly to later exposures, even after the original allergen is gone.
The Terasaki Institute faculty has developed a next-generation immunomodulatory wound dressing platform designed to accelerate healing in chronic wounds. The platform is designed to deliver oxygen directly to the wound and use a specialized peptide to encourage immune cells to support healing.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
The cGAS-STING pathway connects cellular aging to brain inflammation, with self-DNA accumulating in the cytoplasm and triggering chronic inflammation. Mitochondrial DNA plays a key role in this process, linking metabolic dysfunction to glial activation and neuronal damage.
Researchers discovered that gut bacteria produce vaccenic acid, a substance that activates the LRH-1 receptor, improving metabolic health and reducing inflammation. The study highlights the crucial role of the gut microbiome in regulating physiological processes and overall metabolism.
Researchers develop a new approach combining probiotics with T cells to improve tumor localization and coordination of local immune responses. The therapy, called T-FOLactis, shows improved tumor control and median survival in mouse colorectal cancer models.
Christopher Goodnow's work challenged the concept of complete clonal deletion, revealing self-reactive B cells' ability to acquire self-tolerance and potentially cause autoimmune disease. His research discovered that these cells are essential for immune function and can be converted into functional B cells through 'clonal redemption'.
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
XKH004 effectively improves ankylosing spondylitis symptoms and physical functions over 52 weeks, with significant increases in clinical remission and reductions in systemic inflammation and pain. Long-term safety performance is stable and controllable, making it a promising treatment option for refractory patients.
Salk Institute researchers have discovered a novel pathway that links chronic interferon II exposure to mitochondrial dysfunction, leading to immunosuppression and enhanced tumor growth. By blocking prostaglandin E2, they found a viable target to restore immune system function and combat immunotherapy resistance.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
A team of researchers from the University of Osaka found that cells producing IgG1 antibodies have advantages over those producing IgM antibodies, including better antigen presentation, survival, and bone marrow migration. These advantages may lead to long-term immune protection and inform the development of more effective vaccines.
A new strategy has been developed to help macrophages stay active inside tumors. Tiny patches are attached to macrophages, which break down and release zinc ions to activate the immune system. This approach combines immune-cell reprogramming with tumor-environment remodeling, helping macrophages regain anti-tumor activity.
A modular nano-adaptor approach tunes T-cell activation to control CD3 activation and prevent toxicity, increasing therapeutic effectiveness in solid tumors. The platform has identified promising lead designs for multispecific nanoantibody configurations.
mRNA-LNPs are shifting the paradigm of drug delivery, enabling vaccines, personalized cancer vaccines, and in vivo gene editing. CAR-engineered cells can be directly generated in vivo, offering a streamlined alternative to ex vivo CAR-T manufacturing.
Cancer cells release natural antioxidants, such as Peroxiredoxin 1, to suppress immune-cell activity and prevent destruction. Removing this antioxidant production enhances the cancer's response to immunotherapy.
Salk Institute scientists found that maternal immune activation leads to epigenetic changes in mouse brains, increasing the risk of neurodevelopmental disorders. These changes were particularly significant in areas of the genome associated with autism spectrum disorder.
Research reveals UBE2M's critical regulatory link to inflammation and innate immune pathway in KrasG12D driven non-small cell lung cancer. Simultaneous UBE2M deletion and KrasG12D activation causes severe inflammatory TME, shortening life-span and promoting tumor growth.
Researchers have created a detailed map of childhood Crohn's disease before and after treatment, identifying specific cell signatures that predict disease severity and treatment outcomes. The study suggests that anti-TNF therapy may push the pediatric cell ecosystem towards more resistant disease.
Children's Hospital Colorado has launched a Sublingual Immunotherapy Program to treat children with 10 common food allergies, including milk, egg, peanut, and sesame. The program involves daily liquid drops under the tongue and may gradually build tolerance and provide greater protection against accidental exposure.
Immunotherapy for gynecological tumors offers durable responses and survival benefits, but complex immune evasion mechanisms and tumor microenvironment pose challenges. Current treatment options, such as ICIs and adoptive cell therapy, show promise, but precision immunotherapy is needed to improve patient outcomes.
Tumor-infiltrating lymphocyte therapy has shown potential in several types of solid tumors, including metastatic melanoma, breast cancer, and ovarian cancer. Despite challenges, the approach has favorable clinical outcomes, and researchers are exploring combination strategies and advanced technologies to improve treatment durability.
Researchers have identified a subset of B cells known as atypical memory cells as the primary precursors of autoantibody-producing cells during SARS-CoV-2 infection. These cells adopt a markedly different biological program, leading to increased autoantibody production. The study provides new insight into how viral infections can trigg...
Researchers discovered how tumors interact with the body to grow and spread, revealing a new target for cancer therapy. Metadherin, a protein encoded by the MTDH gene, mediates this metabolic-immune crosstalk, supporting tumor growth and metastasis.
Researchers have created a high-resolution functional map of human immune cells, revealing intricate circuits that govern health and disease. The dataset provides a powerful framework for designing cancer immunotherapies and treating autoimmune conditions, and serves as a foundation for AI models of biology.
Researchers have identified a hidden defect in the gut that can damage intestinal cells, even in patients with well-controlled disease. The study found that this defect can be present in patients with clinically mild disease and can lead to future flares.
A review by Professor Di Wang and Dr. Zheyu Chi proposes a conceptual framework in which immunometabolism is shaped by the local repair niche, influencing tissue repair trajectories. Organ-specific metabolic microenvironments uniquely shape immune cell function, necessitating targeted therapeutic interventions.
Researchers found that dietary tryptophan supplementation can prevent sepsis by enhancing macrophage bacterial defense through GPR37 activation, which increases phagocytic ability against bacteria. IPyA, a key metabolic product, directly binds to GPR37 on macrophages, activating RAC1/CDC42 and increasing phagocytosis.
Researchers found that alveolar type 2 cells mount slower interferon-driven antiviral defenses than type 1 cells, enabling higher viral replication in the alveoli. This study provides new insights into the primary site of influenza virus damage and opens up potential targets for antiviral therapy.
Scientists have identified multiple targets for antibodies that could treat Crimean-Congo hemorrhagic fever, a deadly virus spread by ticks. The research found that antibodies targeting the nucleocapsid protein offer protection against the virus, regardless of strain, and could lead to the development of new treatments.
Researchers discovered that Trypanosoma cruzi, the Chagas disease parasite, alters its RNA to adapt to infect mammals, a process that could lead to new treatments. The study found that modifications in transfer RNA facilitate protein production, influencing the parasite's transformation from a non-infective to an infectious phase.
Researchers review glioma microenvironment and related therapeutic strategies, highlighting the need to disrupt neuron-tumor communication and reprogram the immune landscape. This review provides a conceptual framework for next-generation therapies and marks a fundamental shift in glioma therapeutics.
Researchers from the University of Osaka have found a rare type of immune cell that expands in supercentenarians, potentially helping protect against cancer and other age-related threats. The cells, known as CD4 CTLs, have been shown to be highly active and may help the body cope with persistent threats that increase with age.
Scripps Research scientist Tiantian Liu has received a $2.76 million NIAID New Innovators Award to study immune cell biology and develop new therapies that harness T cell responses. Her research aims to advance fundamental knowledge of how immune cells activate T cells to combat infectious diseases.
A study led by German Cancer Research Center researchers found that the WNT signaling pathway helps cancer cells suppress the immune system, promoting the development of malignant tumors. Restoration of CCL20 production slowed tumor growth in experimental models.
Researchers at MIT developed a new cell-preservation technique using naturally occurring sugars, reducing the need for a chemical preservative. This approach significantly improves the viability and function of CAR-T cells, making them easier to deploy in hospitals.
Researchers discovered that exhausted T cells can lose the exhaustion marker LAG3 to escape tumors and confer long-lasting immunity to cancer in mice. These cells play a critical role in generating a strong, durable memory response, which is essential for effective cancer immunotherapy.
A new book by University of Virginia Health System expert Daniel J. Cox outlines a practical alternative to medication for managing pre-diabetes and type 2 diabetes. The GEM program emphasizes smart eating, physical activity, and listening to the body to regulate blood sugar levels.
Researchers discovered a unique macrophage subset in pneumocystis pneumonia, which exhibited strong anti-inflammatory features and activated pro-proliferative pathways. Pharmacological inhibition of the MAPK pathway reversed this expansion, reducing immune suppression and paving the way for novel treatments.
Researchers uncover the placenta distinguishes between antibodies and albumin, allowing for the design of long-acting biologic medicines with reduced fetal exposure. Fusion of IgG antibodies to albumin inhibits transport across the placenta, enabling the development of safer treatments during pregnancy.
The DKMS John Hansen Research Grant supports innovative cell therapy approaches and transplant immunology. The grant enables young researchers to build a network and advance lifesaving therapies for blood cancer.
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
A coral-inspired 3D-printed scaffold reprograms immune cells to promote angiogenesis and bone regeneration, shifting macrophages from inflammatory M1 state to reparative M2 state. The scaffold also enhances angiogenesis, new bone formation, and reconstruction of bone defects.
A single-cell atlas reveals that a balance between two macrophage states, with lipid-fueled immunesupressors, tracks clinical outcomes in gastric cancer patients. Tumors with a more permissive immune state respond better to immunotherapy and have longer progression-free survival.
A protein known for sensing cellular stress also acts as a cholesterol sensor in specialized immune cells, enabling them to process dying cells and maintain immune homeostasis. IRE1's removal leads to cholesterol accumulation, negatively affecting cell survival and immune function.
Researchers develop new CAR-T engineering strategies to address the barriers of solid tumors, including tumor access, targeting specificity, cellular resilience, and patient physiological context. The approaches aim to build cellular fitness and overcome immunosuppressive signals, with promising results in clinical trials.
Researchers identified two immune cell populations present in both initial and recurrent arthritis flares, suggesting an immune-memory disease. These cells may serve as biomarkers for high-risk patients or to guide targeted therapies to reduce side effects.
National Jewish Health researchers identified disease-associated gene activity in macrophages and changes in immune cell communication in lung tissue. These findings may lead to targeted therapies and improved diagnosis of pulmonary sarcoidosis.
Researchers explore bacterial extracellular vesicles as a tool for cancer diagnosis and treatment, with potential for targeted delivery of therapeutic molecules and immunotherapy. However, consistency and safety remain major challenges in this emerging field.
Researchers found that infected tadpoles preferred cooler temperatures and regulated their body temperature to slow viral replication. The study suggests that behavioural cooling may help animals combat viral infections, providing a physiological advantage over the detrimental effects of low temperatures.